Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Fisher received his MD from the University of Massachusetts Medical School in 1989 and residency training in internal medicine at the Duke University Medical Center, where he also served clinical fellowships in infectious diseases, hematology-oncology, and bone marrow transplantation. In 1995, he joined DFCI, where his clinical practice specializes in the treatment of patients with non-Hodgkin's lymphoma, and Hodgkin's disease.
Our primary focus is the comprehensive treatment of patients with non-Hodgkin's lymphoma, Hodgkin's disease, and chronic lymphocytic leukemia (CLL). This clinical work includes the expert use of chemotherapy, radiation therapy, and stem cell transplant procedures. Our practice, located at the Lymphoma Clinic at Dana-Farber, is a combined clinic that includes radiation oncologists who specialize in lymphoma. Dr. Fisher attends on the Lymphoma and Bone Marrow Transplant services at the Brigham and Women's Hospital, and is the oncologist providing specialty care in the Cutaneous Lymphoma Clinic in conjunction with the Department of Dermatology. This large-volume practice allows us to provide expertise in all types of lymphoma.Our research interests are in the use of novel drug combinations to improve therapy for different subtypes of lymphoma, and in the evolving field of immunotherapies and radioimmunotherapies for this population of patients. We are also conducting clinical trials evaluating the use of high-dose chemotherapy with autologous or allogeneic bone marrow transplant. The latter includes the use of ablative and nonmyeloablative preparative regimens with both related and unrelated donors. The focus of these studies is the optimal use of each of these strategies for the many types of non-Hodgkin's lymphoma and Hodgkin's disease. This focus allows for continuity of care for patients with lymphoma who require expert management of these modalities.
Dana-Farber Cancer Institute450 Brookline AvenueDana D1B08Boston, MA 02215Get Directions